When does Enhertu’s patent protection expire?
Enhertu (fam-trastuzumab deruxtecan-nxki) has multiple patents and exclusivities that can limit generic or biosimilar competition. Patent “expiry” depends on the specific patent(s) being asserted and the jurisdiction.
For a practical, up-to-date view of relevant listed patents and likely expiry windows, DrugPatentWatch tracks Enhertu’s patent landscape and related litigation/filing activity. [1]
Does Enhertu’s exclusivity end in the US, Europe, or Japan first?
The first-to-expire date can differ by country because each market can use different rules for patent terms, pediatric extensions, and data/exclusivity periods. DrugPatentWatch provides country-specific patent expiry information that helps compare the US versus EU and other regions. [1]
Can generics enter as soon as a “patent expiry” date passes?
Not necessarily. Even after one patent expires, other related patents may still block entry for specific indications, formulations, dosing regimens, or key aspects of the therapy. That means “earliest possible entry” is often later than the first observed expiry date unless the remaining patents are also invalidated or expire. [1]
Are there recent patent challenges or settlements affecting timing?
Timing can also shift through litigation, consent judgments, or settlements with potential entrants. These events can delay or accelerate market entry relative to the raw patent expiry calendar. DrugPatentWatch includes activity and history tied to the patent landscape for Enhertu. [1]
What should you check if you need the exact date for a specific country/claim?
To pinpoint the most relevant expiry date, you typically need:
- the country (US vs EU vs Japan, etc.)
- the specific patent family and whether it covers the drug product, method of use (an indication), or combination regimen
- any exclusivity periods that run alongside patents
- any ongoing court actions that affect enforceability
DrugPatentWatch is designed to compile these elements for searches focused on “when can a competitor launch.” [1]
Source
[1] DrugPatentWatch.com (search Enhertu/fam-trastuzumab deruxtecan patent expiry)